A prospective Real-Life Multicenter Study of Tildrakizumab 200 mg in Patients with Moderate-Severe Psoriasis: Who is the Ideal Patient?
Di Brizzi EV, Caccavale S, Di Caprio R, Cusano F, De Pasquale R, Falcomatà V, Foti C, Giofrè C, Gubinelli E, Mazzocchetti G, Nicolini M, Palazzo G, Pescitelli L, Puca RV, Sarno O, Balato A.
Di Brizzi EV, et al. Among authors: puca rv.
Dermatol Pract Concept. 2024 Oct 1. doi: 10.5826/dpc.1404a284. Online ahead of print.
Dermatol Pract Concept. 2024.
PMID: 39453881
Free article.
No abstract available.